[go: up one dir, main page]

PE20010406A1 - ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd - Google Patents

ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd

Info

Publication number
PE20010406A1
PE20010406A1 PE2000000630A PE0006302000A PE20010406A1 PE 20010406 A1 PE20010406 A1 PE 20010406A1 PE 2000000630 A PE2000000630 A PE 2000000630A PE 0006302000 A PE0006302000 A PE 0006302000A PE 20010406 A1 PE20010406 A1 PE 20010406A1
Authority
PE
Peru
Prior art keywords
methyl
phenoxy
trifluoromethyl
phenyl
acetic acid
Prior art date
Application number
PE2000000630A
Other languages
English (en)
Inventor
Esther Yu-Hsuan Chao
Curt Dale Haffner
Iii Millard Hurst Lambert
Patrick Reed Maloney
Michael Lawrence Sierra
Timothy Mark Willson
Daniel David Sternbach
Marcos Luis Sznaidman
Huaqiang Eric Xu
Francoise Jeanne Gellibert
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20010406A1 publication Critical patent/PE20010406A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A COMPUESTOS DE TIAZOL Y OXAZOL DE FORMULA I, DONDE: X ES COOH, TETRAZOL; X1 ES NH, NCH3, O, S, UN ENLACE; X2 ES O, S; R1 Y R2 SON H, CH3, OCH3, HALOGENO; n ES 1-2; UNO DE Y O Z ES N Y EL OTRO ES S U O; y ES 0-5; R3 ES CF3, HALOGENO. SON COMPUESTOS PREFERIDOS ACIDO 2-[2-METIL-4-({4-METIL-2-[4-(TRIFLUOROMETIL)FENIL]-1,3-OXAZOL-5-IL}METOXI)FENOXI]ACETICO; ACIDO 2-{2-METIL-4-[({4-METIL-2-[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO, ENTRE OTROS. EL COMPUESTO I ES UN AGONISTA DEL RECEPTOR ACTIVADO POR EL PROLIFERADOR DEL PEROXISOMA HUMANO hPPARÙ Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISLIPIDEMIA, SINDROME X, ATAQUE CARDIACO, HIPERCOLESTEROLEMIA, ENFERMEDAD CARDIOVASCULAR, DIABETES, OBESIDAD, ANOREXIA
PE2000000630A 1999-06-25 2000-06-23 ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd PE20010406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914977.5A GB9914977D0 (en) 1999-06-25 1999-06-25 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20010406A1 true PE20010406A1 (es) 2001-04-10

Family

ID=10856125

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000630A PE20010406A1 (es) 1999-06-25 2000-06-23 ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd

Country Status (29)

Country Link
US (2) US6710063B1 (es)
EP (1) EP1189895B8 (es)
JP (2) JP3490704B2 (es)
KR (1) KR100668026B1 (es)
CN (1) CN1164579C (es)
AR (1) AR035320A1 (es)
AT (1) ATE297384T1 (es)
AU (1) AU765347B2 (es)
BR (1) BR0011891A (es)
CA (1) CA2377126C (es)
CO (1) CO5180622A1 (es)
CZ (1) CZ300654B6 (es)
DE (1) DE60020701T2 (es)
ES (1) ES2243276T3 (es)
GB (1) GB9914977D0 (es)
HK (1) HK1042897B (es)
HU (1) HUP0201858A3 (es)
IL (2) IL146634A0 (es)
MX (1) MXPA01013244A (es)
MY (1) MY120090A (es)
NO (1) NO321872B1 (es)
NZ (1) NZ515676A (es)
PE (1) PE20010406A1 (es)
PL (1) PL353135A1 (es)
PT (1) PT1189895E (es)
TR (1) TR200103612T2 (es)
TW (1) TWI256389B (es)
WO (1) WO2001000603A1 (es)
ZA (1) ZA200109804B (es)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
RS50406B (sr) 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
US7078422B2 (en) * 2001-03-23 2006-07-18 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
WO2002083131A1 (en) * 2001-04-13 2002-10-24 The Regents Of The University Of California Activators and ligands of ppar-beta/delta for the treatment of skin conditions
KR100654516B1 (ko) * 2001-05-15 2006-12-05 에프. 호프만-라 로슈 아게 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
WO2003008967A1 (en) 2001-07-17 2003-01-30 Teijin Limited Method of selecting substance characterized by assaying ppard activating effect and drug
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
BRPI0211844B8 (pt) * 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
BR0212512A (pt) 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
ES2316736T3 (es) 2002-02-25 2009-04-16 Eli Lilly And Company Moduladores de receptores activados por proliferador de peroxisoma.
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2003213281A1 (en) * 2002-02-28 2003-09-16 Smithkline Beecham Corporation Process and intermediates for preparing phenylthiomethyl-thiazoles or oxazoles
JP4383177B2 (ja) * 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
US6833380B2 (en) * 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6716842B2 (en) * 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
EP1513817A1 (en) * 2002-05-24 2005-03-16 Takeda Pharmaceutical Company Limited 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity
JP2004277397A (ja) * 2002-05-24 2004-10-07 Takeda Chem Ind Ltd １，２−アゾール誘導体
EP1519925B1 (en) * 2002-07-03 2007-09-12 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
HRP20050001A2 (en) * 2002-07-09 2005-08-31 Bristol-Myers Squibb Company A Delaware (Usa) Corp Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
RU2296754C2 (ru) * 2002-08-30 2007-04-10 Ф.Хоффманн-Ля Рош Аг НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ
US7091245B2 (en) 2002-09-05 2006-08-15 Novo Novdisk A/S Compounds, their preparation and use
WO2004024705A1 (ja) * 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited ５員複素環化合物
JP2004123732A (ja) * 2002-09-10 2004-04-22 Takeda Chem Ind Ltd ５員複素環化合物
ES2275105T3 (es) 2002-09-12 2007-06-01 F. Hoffmann-La Roche Ag Compuestos de acido 1-h-indol-5-propionico n-sustituidos como agonistas ppar utiles para el tratamiento de diabetes.
US7162262B2 (en) 2002-09-23 2007-01-09 Telefonaktiebolaget Lm Ericsson (Publ) Methods, systems and computer program products for requesting received power levels based on received block error rates utilizing an anti-windup and/or emergency procedure
ES2344106T3 (es) 2002-10-28 2010-08-18 High Point Pharmaceuticals, Llc Nuevos compuestos utiles en el tratamiento de enfermedades mediadas por ppar.
EP1558572B1 (en) 2002-10-28 2010-06-30 High Point Pharmaceuticals, LLC Novel compounds and their use as prar-modulators
US7129268B2 (en) 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
PL377320A1 (pl) 2002-11-25 2006-01-23 F. Hoffmann-La Roche Ag Pochodne indolilowe
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US7384965B2 (en) 2003-01-06 2008-06-10 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
DE10308354A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
PT1667964E (pt) 2003-09-19 2009-09-02 Janssen Pharmaceutica Nv Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos
NZ545971A (en) 2003-09-19 2009-09-25 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
BRPI0414580A (pt) 2003-09-22 2006-11-07 Ono Pharmaceutical Co derivado do ácido fenilacético, processos para sua produção e uso
WO2005051373A1 (ja) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
EP1697339A1 (en) 2003-12-25 2006-09-06 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7816367B2 (en) * 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
BRPI0509540A (pt) * 2004-04-01 2007-09-18 Aventis Pharma Inc uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
RU2375358C2 (ru) * 2004-04-01 2009-12-10 Авентис Фармасьютикалз, Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение
EP1781648A2 (en) * 2004-04-01 2007-05-09 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
JP2007269630A (ja) * 2004-06-23 2007-10-18 Toudai Tlo Ltd インスリン分泌促進剤
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JP2008517902A (ja) * 2004-10-22 2008-05-29 ホンジュン カン アルキルアリルサルファイド誘導体の製造方法及び新規なサルファイド化合物
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2006057448A1 (ja) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
ATE539066T1 (de) * 2004-12-31 2012-01-15 Seoul Nat Univ Ind Foundation Organoselenhaltige verbindungen und deren verwendung
RU2371437C2 (ru) * 2004-12-31 2009-10-27 Сеул Нэшнл Юниверсити Индастри Фаундейшн Селенорганические соединения и их применение
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
KR100797798B1 (ko) * 2005-02-25 2008-01-24 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 델타 리간드 티아졸 유도체및 그의 제조방법
JP4869338B2 (ja) * 2005-05-07 2012-02-08 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖因子活性化受容体δリガンドの製造方法及びこれを製造するための中間体
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7781469B2 (en) 2005-05-27 2010-08-24 Shionogi & Co., Ltd. Arylacetate derivatives having isoxazole skeleton
WO2006126541A1 (ja) * 2005-05-27 2006-11-30 Shionogi & Co., Ltd. ビタミンｋ類含有医薬組成物
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
US7582803B2 (en) * 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5183479B2 (ja) * 2005-09-29 2013-04-17 サノフイ フェニル基を有するフェニル−［１，２，４］−オキサジアゾール−５−オン誘導体、その製造方法、及び医薬品としてのその使用
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
ES2386734T3 (es) 2005-12-22 2012-08-28 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-DELTA
JP2009523132A (ja) * 2006-01-10 2009-06-18 スミスクライン ビーチャム コーポレーション ｛２−メチル−４−［４−メチル−２−（４−トリフルオロメチルフェニル）チアゾール−５−イルメチルチオ］フェノキシ｝−酢酸の多形体形態
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
JP5301286B2 (ja) * 2006-02-03 2013-09-25 イーライ リリー アンド カンパニー Ｆｘ受容体を調節するための化合物及び方法
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
NZ572268A (en) * 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2007141295A1 (en) * 2006-06-08 2007-12-13 High Point Pharmaceuticals, Llc Process for preparing phenoxy acetic acid derivatives
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008016175A1 (en) * 2006-08-03 2008-02-07 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor
CA2662242C (en) * 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
EP2061484B1 (en) 2006-09-08 2012-11-07 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
WO2008030604A2 (en) 2006-09-08 2008-03-13 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
CA2669639A1 (en) 2006-12-02 2008-06-05 Seoul National University Industry Foundation Aryl compounds as ppar ligands and their use
AU2007341981A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
EP2104666A4 (en) 2007-01-08 2011-05-25 Seoul Nat Univ Ind Foundation THIAZOL COMPOUND (AS PPAR DELTA LIGAND), AND PHARMACEUTICAL, COSMETIC AND HEALTHY FOOD THEREOF
WO2008103501A1 (en) * 2007-02-22 2008-08-28 Irm Llc Compounds and methods for modulating g protein-coupled receptors
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
WO2008154023A1 (en) * 2007-06-11 2008-12-18 Cerenis Therapeutics S.A. Novel uses of ppar delta agonists
GB0712653D0 (en) 2007-06-28 2007-08-08 Syngenta Ltd Novel herbicides
GB0717082D0 (en) 2007-09-03 2007-10-10 Syngenta Ltd Novel herbicides
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009078981A2 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
MX2010009654A (es) * 2008-03-06 2010-09-28 Amgen Inc Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
JP5474769B2 (ja) 2008-04-15 2014-04-16 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
CA2739888C (en) * 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
ES2712052T3 (es) 2008-10-17 2019-05-09 Cymabay Therapeutics Inc Métodos para reducir partículas de LDL pequeñas y densas
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2612669A4 (en) * 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
US9695137B2 (en) * 2013-03-14 2017-07-04 The University Of Toledo Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same
US10181018B2 (en) * 2013-03-14 2019-01-15 The University Of Toledo Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
EP3871667A4 (en) * 2018-10-23 2022-08-17 Japan Science and Technology Agency PPAR DELTA ACTIVATOR
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS644688A (en) * 1987-06-26 1989-01-09 Tokuyama Soda Kk Photochromic composition
JPH0793082B2 (ja) * 1987-09-07 1995-10-09 株式会社明電舎 真空インタラプタの化成方法
JP2551151B2 (ja) * 1989-06-22 1996-11-06 神鋼電機株式会社 潜熱回収方式の給湯装置における放熱装置
JP3039009B2 (ja) * 1991-06-25 2000-05-08 ソニー株式会社 固体撮像素子の駆動装置
TW268952B (es) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
JP3466273B2 (ja) 1993-06-11 2003-11-10 武田薬品工業株式会社 テトラゾール誘導体、その製造法およびそれを含んでなる医薬
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
JP3836521B2 (ja) 1994-08-10 2006-10-25 武田薬品工業株式会社 ２，４−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
JP2850809B2 (ja) 1994-11-02 1999-01-27 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体およびそれを含んでなる医薬組成物
JP3880108B2 (ja) 1994-11-02 2007-02-14 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
CZ53699A3 (cs) * 1996-08-19 1999-07-14 Japan Tobacco Inc. Deriváty propionové kyseliny a jejich použití
ATE421336T1 (de) * 1997-07-24 2009-02-15 Astellas Pharma Inc Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
KR102220553B1 (ko) * 2015-03-10 2021-02-26 한국전자통신연구원 표시 패널 및 그것을 포함하는 표시 장치

Also Published As

Publication number Publication date
AU765347B2 (en) 2003-09-18
ES2243276T3 (es) 2005-12-01
HK1042897A1 (en) 2002-08-30
JP2003313141A (ja) 2003-11-06
EP1189895B1 (en) 2005-06-08
CA2377126A1 (en) 2001-01-04
EP1189895A1 (en) 2002-03-27
PL353135A1 (en) 2003-10-20
CA2377126C (en) 2009-01-27
TWI256389B (en) 2006-06-11
WO2001000603A1 (en) 2001-01-04
US20030203947A1 (en) 2003-10-30
CO5180622A1 (es) 2002-07-30
EP1189895B8 (en) 2005-11-09
MXPA01013244A (es) 2002-07-02
CN1358179A (zh) 2002-07-10
IL146634A0 (en) 2002-07-25
ATE297384T1 (de) 2005-06-15
AR035320A1 (es) 2004-05-12
DE60020701T2 (de) 2006-05-04
CZ20014664A3 (cs) 2002-03-13
IL146634A (en) 2007-10-31
NO321872B1 (no) 2006-07-17
NO20016078L (no) 2001-12-13
AU5817100A (en) 2001-01-31
HK1042897B (en) 2005-12-02
TR200103612T2 (tr) 2002-05-21
ZA200109804B (en) 2003-02-28
HUP0201858A2 (en) 2002-09-28
US6723740B2 (en) 2004-04-20
BR0011891A (pt) 2002-03-05
DE60020701D1 (de) 2005-07-14
GB9914977D0 (en) 1999-08-25
MY120090A (en) 2005-08-30
CN1164579C (zh) 2004-09-01
NZ515676A (en) 2004-05-28
KR20020015358A (ko) 2002-02-27
KR100668026B1 (ko) 2007-02-28
JP3490704B2 (ja) 2004-01-26
HUP0201858A3 (en) 2004-12-28
PT1189895E (pt) 2005-10-31
US6710063B1 (en) 2004-03-23
CZ300654B6 (cs) 2009-07-08
JP2003503399A (ja) 2003-01-28
NO20016078D0 (no) 2001-12-13

Similar Documents

Publication Publication Date Title
PE20010406A1 (es) ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd
PE20011010A1 (es) Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US7183295B2 (en) PPAR-activating compound and pharmaceutical composition comprising the compound
US7652045B2 (en) Activator of peroxisome proliferator-activated receptor δ
RU2312106C2 (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
PE20010529A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
PE20000947A1 (es) ACTIVADORES DE hPPARþ Y hPPARO
PE20021117A1 (es) Compuestos agonistas del receptor activador del proliferador de peroxisomas (ppar)
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
JP2005529077A (ja) ペルオキシソーム増殖因子活性化受容体調節物質
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20080185A1 (es) Analogos de anilino-pirimidina fenilo y benzotiofeno
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
PE20110299A1 (es) Nuevos derivados de acilaminobenzamida
EP1701722A4 (en) N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOLE-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2 METHANSULFONE ACID SALT
PE20120667A1 (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
PE20010858A1 (es) Derivados de tiazolidindiona como agentes antidiabeticos
RU2007111123A (ru) Производные арилсульфонилстильбена для лечения бессоницы и связанных с ней расстройств
RU2006138485A (ru) 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение
PE20030943A1 (es) Agonistas del receptor b3-adrenergico
US7919515B2 (en) 3-phenylpropionic acid derivatives
JP2007522178A5 (es)
RU2369602C2 (ru) Новые производные 3-фенилпропионовой кислоты
BR9507014A (pt) Derivados de tiazolidinadiona como agentes antihiperglicémicos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed